Last updated: 02/04/2020 15:50:10
Prevalence of the metabolic syndrome among men with and without benign prostatic hyperplasia
GSK study ID
201401
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Prevalence of the metabolic syndrome among men with and without benign prostatic hyperplasia
Trial description: Many scientific publications have found that certain characteristics tend to occur together in patients, for example, diabetes, high blood pressure, high cholesterol, and being overweight. When several of these characteristics are present in the same patient, it is referred to as the metabolic syndrome. Several scientific studies have found that the metabolic syndrome may cause benign prostatic hyperplasia (BPH) or increase the severity of this condition. This study will describe the occurrence of the metabolic syndrome in men with and without BPH and will provide some initial information concerning whether or not the occurrence these two conditions might be related.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Prevalence of the metabolic syndrome
Timeframe: At the time of analysis
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
0
Primary completion date:
2014-04-08
Observational study model:
Cohort
Time perspective:
Retrospective
Clinical publications:
Not applicable
- Patients in the CPRD database with or without BPH
- Age >= 50 years
Inclusion and exclusion criteria
Inclusion criteria:
- Patients in the CPRD database with or without BPH
- Age >= 50 years
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
No study documents available
Recruitment status
Study complete
Actual primary completion date
2014-04-08
Actual study completion date
2014-04-08
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website